AB-Biotics and GlaxoSmithKline sign an agreement to promote the test Neurofarmagen in Brazil
· The Spanish biotech company traded on the MAB partners with GlaxoSmithKline to promote its genetic analysis in the Latin American giant market, with 1 million potential beneficiaries
· With the DNA extracted from a saliva sample, Neurofarmagen allows the physician to identify the most appropriate treatment for a patient with depression, schizophrenia, bipolar disorder or epilepsy
Barcelona (Spain), March 21st 2013.- GlaxoSmithKline (GSK) and the Spanish biotech company AB-Biotics, listed on the Spanish Alternative Stock Market (MAB), have reached an agreement by which GSK will handle the exclusive promotion of Neurofarmagen, the line of pharmacogenetic tests developed by AB-Biotics.
"The agreement with GlaxoSmithKline will be a major boost for the AB-Biotics turnover in the coming years", said Miquel Angel Bonachera and Sergi Audivert, co-founders and CEOs of AB-Biotics.
GSK will promote in Brazil Neurofarmagen, a genetic test developed by AB-Biotics which identifies the safest and most appropriate medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing their DNA, extracted from a sample of saliva. The product will be launched this year in Brazil, where according to estimates by AB-Biotics, there are 1 million potential patients eligible for Neurofarmagen. In Spain, this test is currently marketed by Almirall following the agreement signed last October by this Spanish pharmaceutical company and AB-Biotics.
AB-Biotics is a Spanish biotechnology company focused on research, development, protection and distribution of its own exclusive biotechnological solutions for human health. Since 2010, the company is listed on the Spanish Alternative Investment Market (MAB). AB-Biotics develops innovative products in the Nutraceutical and Pharmacogenetic areas, which are currently being sold in Europe, America and Asia. In December 2012, AB-BIOTICS closed a fundraising round of 5 million euros to bolster the company's internationalization plan.
GlaxoSmithKline (GSK), one of the world's leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Chief Communications Officer
Tel. 0034 654 352 541